<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anagnostopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Aleman, A.</style></author><author><style face="normal" font="default" size="100%">Weber, D.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author><author><style face="normal" font="default" size="100%">Champlin, R.</style></author><author><style face="normal" font="default" size="100%">Giralt, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia</style></title><secondary-title><style face="normal" font="default" size="100%">Bone Marrow Transplantation</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Allogeneic stem cell transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">ASCT</style></keyword><keyword><style  face="normal" font="default" size="100%">High-dose chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Waldenström's macroglobulinemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2001</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034962024&amp;doi=10.1038%2fsj.bmt.1703041&amp;partnerID=40&amp;md5=50ae2a6a27cf5d5c554de2845747baae</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">1027 - 1029</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Preliminary evidence suggests that high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation may be effective in some patients with resistant Waldenstrom's macroglobulinemia. During the last 10 years, seven patients with Waldenstrom's macroglobulinemia have received transplants at the MD Anderson Cancer Center, four with autologous and three with allogeneic stem cells. Four patients achieved partial remission, and three patients have remained alive for at least 2 years. Our data confirm the feasibility of high-dose therapy in patients with macroglobulinemia and support the need for prospective studies of this modality in patients with chemosensitive disease.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :43Export Date: 21 February 2017</style></notes></record></records></xml>